N4 Pharma PLC (N4P)
Industry Drug Manufacturers - Specialty & Generic
This stock can be held in an Investment ISA, SIPP and Investment Account
Sell
0.40p
Buy
0.45p
0.005p (+1.18%)
N4 Pharma PLC is a specialist pharmaceutical company which reformulates existing drugs and vaccines to improve their performance. Its vaccines include Nuvac and Nuvec.
Prices updated at 01 May 2025, 16:35 BST
| Prices minimum 15 mins delay
|
Prices in GBX
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
- Key stats
- Price
- Fair value
- Dividends
- News
- Financials
- Valuation
- Profile
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Chairman
Dr. Christopher Jonathan Britten
CEO
Mr. Nigel Theobald
Most recent earnings
31 Dec 2023
Fiscal year end
31 Dec 2023
Employees
5
Head office
60 Gracechurch Street
London
United Kingdom
EC3V 0HR
Key personnel
| Owner name | Salary | Bonus | All other compensation | Total compensation | Restricted stock award |
|---|---|---|---|---|---|
Dr. Christopher Jonathan Britten Non-Executive Director, Chairman | - | - | - | 0.02m | - |
Dr. Michael G. Palfreyman Non-Executive Director | - | - | - | - | - |
Dr. David Alastair Maclaughlin Smith Non-Executive Director | - | - | - | - | - |
Mr. Nigel Theobald Executive Director, Chief Executive Officer | - | - | - | - | - |
Mr. Luke Sebastian Cairns Executive Director | - | - | - | - | - |
Top 5 shareholders
| Owner name | No. of shares | Share as % of port. | Last change | Portfolio % change | Date of portfolio | % Total assets |
|---|---|---|---|---|---|---|
| No data | ||||||
Director dealings
| Date | Action | Name | Price | Value | No. of shares | Holding (%) | Additional info |
|---|---|---|---|---|---|---|---|
| 04 Apr 2025 | Purchase | Dr. David Alastair Maclaughlin Smith | 0.40 | 3,264 | 815,888 | 0.21 | Placing |
Please note that past performance is not a reliable indicator of future returns.
